BAXTER INTERNATIONAL INC — Form 8-K
Filed July 14, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 32/100
What the filing says
Baxter posted 2025 net sales of $11.244B (reported growth 6%, operational growth 3%). Full-year 2025 segment operating income: Medical Products & Therapies $1,681M, Healthcare Systems & Technologies $565M. Q1 2026 (ended March 31) reported sales $2.701B with organic growth of –1% due to currency headwinds (–3%) and Kidney Care MSA impact (–1%), partially offset by reported growth of +3%. Multiple non-GAAP charges: $290M indefinite-lived asset impairments, $485M goodwill impairments, $133M Hurricane Helene costs in 2025; Q1 2026 saw $66M operating loss before interest.
Why this rating
Organic growth turning negative in latest quarter, large goodwill/impairment charges, and operating losses indicate operational stress, but event is routine periodic disclosure relative to $16B market cap.
See more from July 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.